Press Release For Immediate Release

Glenmark confirms patent infringement suit for Hydrocortisone Butyrate

- Glenmark believes it is the first applicant to file an ANDA with a para IV certification on the product

Monday, November 8, 2010 : Glenmark Pharmaceuticals Limited and Glenmark Generics Inc., USA ("Glenmark") confirm Triax Pharmaceuticals, LLC, Astellas Pharma Europe B.V. and Astellas Pharma International B.V. ("Astellas and Triax") have filed a patent infringement suit on November 4, 2010 in the U.S. District Court for the District of Delaware seeking to prevent Glenmark from commercializing its Abbreviated New Drug Application (ANDA) for Hydrocortisone Butyrate cream 0.1%, their generic version of Locoid Lipocream®, prior to expiration of the Orange Book patent.

Astellas and Triax's suit was filed under the provisions of the Hatch-Waxman Act resulting in a stay of final FDA approval of Glenmark's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner. Based on information published by the U.S. FDA, Glenmark believes it is the first applicant to file an ANDA with a paragraph IV certification for a generic version of Locoid Lipocream®, and should its product be approved Glenmark will be entitled to 180 days of generic market exclusivity.

For the twelve-month period ending September 2010, Locoid Lipocream® achieved sales of USD 38 million according to IMS Health.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.

GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com